- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy
Jonathan Barratt et al. · New England Journal of Medicine · 2026
- Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy
Yuzhou Zhang et al. · Kidney International Reports · 2026
- SEISMIC: a multistakeholder summit addressing access issues in diagnosis and treatment of C3G nephropathy and IC-MPGN
Carla Nester et al. · Kidney International · 2026
- Outcomes from the International Society of Nephrology forum on complement therapeutics in C3 glomerulopathy and IgA nephropathy
David Kavanagh et al. · Kidney International · 2026
- Fluid balance and acute lung injury in children and young adults receiving continuous renal replacement therapy: a report from the Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK)
Zachary A. Rumlow et al. · European Journal of Pediatrics · 2026
- Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis.
Raed N. Bou Matar et al. · UNC Libraries · 2026
- A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab
Naga Sumanth Reddy Gopireddy et al. · Clinical Kidney Journal · 2026
- Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN
Marina Vivarelli et al. · Clinical Journal of the American Society of Nephrology · 2026
- Use of extracorporeal membrane oxygenation in neonates with congenital anomalies of the kidney and urinary tract: a multicenter survey of current practices across CHNC and Pedi-ECMO centers
Syed Talha Ahmed et al. · Pediatric Nephrology · 2026
- Fluid accumulation and outcomes in children receiving continuous kidney replacement therapy: an appraisal of the WE-ROCK registry
David T. Selewski et al. · Pediatric Nephrology · 2026